Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

In vivo human amyloid imaging.

Sojkova J, Resnick SM.

Curr Alzheimer Res. 2011 Jun;8(4):366-72. Review.

2.

Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.

Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ.

J Neurosci. 2013 Mar 27;33(13):5553-63. doi: 10.1523/JNEUROSCI.4409-12.2013.

3.

Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.

Förster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Förstl H, Kurz A, Grimmer T, Drzezga A.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1927-36. doi: 10.1007/s00259-012-2230-9. Epub 2012 Aug 28.

PMID:
22926714
4.

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST.

Brain. 2008 Jun;131(Pt 6):1630-45. doi: 10.1093/brain/awn016. Epub 2008 Mar 12.

5.

Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.

Kim CM, Hwang J, Lee JM, Roh JH, Lee JH, Koh JY; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Curr Alzheimer Res. 2015;12(6):563-71.

PMID:
26027813
6.

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2009 May;132(Pt 5):1355-65. doi: 10.1093/brain/awp062. Epub 2009 Mar 31.

7.

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group.

Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23.

PMID:
22628162
8.

Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Cohen AD, Rabinovici GD, Mathis CA, Jagust WJ, Klunk WE, Ikonomovic MD.

Adv Pharmacol. 2012;64:27-81. doi: 10.1016/B978-0-12-394816-8.00002-7. Review.

9.

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC.

Ann Neurol. 2011 Jan;69(1):181-92. doi: 10.1002/ana.22248.

10.
11.

Relationship between memory performance and β-amyloid deposition at different stages of Alzheimer's disease.

Chételat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of Ageing Research Group.

Neurodegener Dis. 2012;10(1-4):141-4. doi: 10.1159/000334295. Epub 2012 Feb 1. Review.

PMID:
22301812
12.

Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA.

J Neurosci. 2005 Nov 16;25(46):10598-606.

13.

Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.

Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Någren K, Tapiola T, Pirttilä T, Rinne J, Jääskeläinen JE, Soininen H, Rinne JO.

Arch Neurol. 2008 Oct;65(10):1304-9. doi: 10.1001/archneur.65.10.noc80013. Epub 2008 Aug 11.

PMID:
18695050
14.
15.

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.

Kadir A, Marutle A, Gonzalez D, Schöll M, Almkvist O, Mousavi M, Mustafiz T, Darreh-Shori T, Nennesmo I, Nordberg A.

Brain. 2011 Jan;134(Pt 1):301-17. doi: 10.1093/brain/awq349. Epub 2010 Dec 13.

16.

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group.

Brain. 2011 Mar;134(Pt 3):798-807. doi: 10.1093/brain/awq383. Epub 2011 Feb 9.

PMID:
21310725
17.

Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid.

Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2011 Mar;7(2):133-41. doi: 10.1016/j.jalz.2010.08.230. Epub 2011 Feb 1.

18.

Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.

Ossenkoppele R, Zwan MD, Tolboom N, van Assema DM, Adriaanse SF, Kloet RW, Boellaard R, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BN.

Brain. 2012 Jul;135(Pt 7):2115-25. doi: 10.1093/brain/aws113. Epub 2012 May 3.

PMID:
22556189
19.

Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.

Driscoll I, Troncoso JC, Rudow G, Sojkova J, Pletnikova O, Zhou Y, Kraut MA, Ferrucci L, Mathis CA, Klunk WE, O'Brien RJ, Davatzikos C, Wong DF, Resnick SM.

Acta Neuropathol. 2012 Dec;124(6):823-31. doi: 10.1007/s00401-012-1025-1. Epub 2012 Aug 5.

20.

Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.

Park JC, Han SH, Cho HJ, Byun MS, Yi D, Choe YM, Kang S, Jung ES, Won SJ, Kim EH, Kim YK, Lee DY, Mook-Jung I.

Alzheimers Res Ther. 2017 Mar 22;9(1):20. doi: 10.1186/s13195-017-0248-8.

Supplemental Content

Support Center